FD
FDMT.US 4D Molecular Therapeutics Inc
- Market cap
- USD 676M
- P/E
- -
- P/B
- 1.64x
- ROE
- -86.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FDMT.US undervalued?
Graham numberThe Graham number of 4D Molecular Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
4D Molecular Therapeutics Inc fundamental analysis
No fundamental analysis for 4D Molecular Therapeutics Inc yet.
4D Molecular Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating…
Full company profile4D Molecular Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
4D Molecular Therapeutics Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 5.79M | 14.1M | 6.99M | 13.6M | 18.0M | 3.13M | 20.7M | 37.0K | 85.2M | 14.6M |
| Gross Profit | -7.78M | -4.23M | -31.7M | -39.4M | 18.0M | 3.13M | -76.4M | -141M | 77.6M | -105M |
| Operating Income | -11.3M | -10.4M | -50.8M | -56.7M | -71.3M | -110M | -113M | -188M | -160M | -309M |
| EBITDA | -10.6M | -9.70M | -44.6M | -55.2M | -68.3M | -106M | -95.1M | -154M | -132M | -291M |
| Net Income | -11.2M | -9.55M | -49.3M | -56.7M | -68.3M | -101M | -101M | -161M | -140M | -293M |
| EPS | -0.76 | -0.76 | -1.86 | -2.12 | -2.46 | -3.12 | -2.58 | -2.98 | -2.42 | -4.06 |
| Balance Sheet | ||||||||||
| Total Assets | 27.3M | 97.0M | 58.2M | 288M | 353M | 262M | 340M | 560M | 567M | 429M |
| Total Liabilities | 46.9M | 125M | 131M | 31.9M | 34.4M | 30.5M | 32.1M | 49.8M | 61.0M | 90.8M |
| Shareholders' Equity | -19.6M | -27.6M | -73.0M | 256M | 319M | 231M | 308M | 511M | 506M | 338M |
| Cash & Short-term Investments | 23.9M | 91.8M | 49.7M | 277M | 248M | 214M | 288M | 425M | 403M | 307M |
| Total Debt | - | - | - | - | 16.4M | 16.1M | 14.7M | 24.6M | 21.4M | 38.4M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 8.24M | -16.3M | -36.7M | -50.9M | -69.1M | -86.7M | -75.8M | -135M | -109M | -260M |
| Capital Expenditure | 573K | 414K | 3.20M | 1.00M | 9.11M | 11.5M | 2.77M | 3.79M | 536K | 139K |
| Free Cash Flow | 7.66M | -16.7M | -39.9M | -51.9M | -78.2M | -98.2M | -78.6M | -138M | -110M | -260M |
| Ratios | ||||||||||
| ROE | - | - | - | -22.1% | -21.4% | -43.7% | -32.8% | -31.5% | -27.7% | -86.7% |
| ROA | -41.1% | -9.8% | -84.7% | -19.7% | -19.3% | -38.6% | -29.7% | -28.7% | -24.7% | -68.3% |
| Net Profit Margin | -193.8% | -67.6% | -705.8% | -416.5% | -378.6% | -3,230.3% | -486.6% | -434,778.4% | -164.4% | -2,002.7% |
| Debt to Equity | - | - | - | - | 0.05x | 0.07x | 0.05x | 0.05x | 0.04x | 0.11x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
4D Molecular Therapeutics Inc dividends
4D Molecular Therapeutics Inc has not paid dividends in the last 9 fiscal years.
Who owns 4D Molecular Therapeutics Inc
- Insiders 2.86%
- Institutions 97.14%
- Public & others 0.00%
- Shares outstanding 55.2M
- Free float 43.4M
Top funds holding FDMT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.59M | 2.88% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.26M | 2.28% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 1.15M | 2.09% | 0.00% | Oct 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 905K | 1.64% | -8.11% | Jun 2026 |
| Janus Henderson Global Life Sciences D | 865K | 1.57% | 0.00% | Sep 2026 |
| Janus Global Life Science AUSD | 854K | 1.55% | +7.64% | Sep 2026 |
| Janus Henderson Glb Life Scn I2 USD | 838K | 1.52% | +5.96% | Aug 2026 |
| T. Rowe Price Small-Cap Stock | 545K | 0.99% | -40.52% | Sep 2026 |
| Fidelity Small Cap Index | 502K | 0.91% | 0.00% | Aug 2026 |
| T. Rowe Price Small-Cap Value | 431K | 0.78% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 426K | 0.77% | 0.00% | Oct 2026 |
| iShares Biotechnology ETF | 391K | 0.71% | -0.19% | Oct 2026 |
| T. Rowe Price Instl Small-Cap Stock | 334K | 0.60% | -32.99% | Sep 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 275K | 0.50% | +0.08% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 273K | 0.49% | -29.91% | Aug 2026 |
| Vanguard Russell 2000 ETF | 267K | 0.48% | +1.28% | Sep 2026 |
| JPM Thmtcs Gentc Thrps C2 dist USD | 236K | 0.43% | -0.83% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 231K | 0.42% | +0.24% | Oct 2026 |
| Fidelity Enhanced Small Cap Core ETF | 231K | 0.42% | +0.27% | Oct 2026 |
| Fidelity Extended Market Index | 208K | 0.38% | +4.24% | Sep 2026 |
Top institutions holding FDMT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 5.75M | 10.40% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 5.05M | 9.14% | 0.00% | Jun 2026 |
| BlackRock Inc | 4.55M | 8.23% | +9.67% | Jun 2026 |
| The Goldman Sachs Group Inc | 4.26M | 7.71% | +1.27% | Jun 2026 |
| Novo A/S | 3.25M | 5.88% | -11.00% | Jun 2026 |
| State Street Corp | 2.91M | 5.27% | +7.51% | Jun 2026 |
| Bvf Inc | 2.88M | 5.21% | 0.00% | Jun 2026 |
| T. Rowe Price Investment Management,Inc. | 2.51M | 4.55% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 2.25M | 4.07% | +40.12% | Jun 2026 |
| Trails Edge Capital Partners, LP | 2.23M | 4.03% | +70.99% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.10M | 3.80% | -4.40% | Jun 2026 |
| Armistice Capital, LLC | 2.00M | 3.62% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 1.13M | 2.04% | +5.92% | Jun 2026 |
| Bank of America Corp | 1.12M | 2.03% | +15.04% | Jun 2026 |
| Parkman Healthcare Partners LLC | 948K | 1.72% | +81.44% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 787K | 1.42% | +7.68% | Sep 2026 |
| Deutsche Bank AG | 711K | 1.29% | +0.41% | Jun 2026 |
| Citadel Advisors Llc | 688K | 1.24% | +160.36% | Jun 2026 |
| Renaissance Technologies Corp | 615K | 1.11% | +6.28% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 580K | 1.05% | +4.33% | Jun 2026 |
4D Molecular Therapeutics Inc company profile
- Company name
- 4D Molecular Therapeutics Inc
- Ticker
- FDMT.US
- Exchange
- USA Stocks
- Listed since
- Dec 11, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 196
- Fiscal year end
- December
- Address
- 5858 Horton Street, EmeryVille, CA, United States, 94608
- Phone
- 510 505 2680
- Website
- 4dmoleculartherapeutics.com
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
4D Molecular Therapeutics Inc management
10- Dr. John F. Milligan Ph.D.Executive Chairman · born 1961
- Dr. David H. Kirn M.D.Co-Founder, President, CEO & Director · born 1962
- Mr. Kristian Humer M.B.A.CFO and Principal Financial & Accounting Officer · born 1976
- Dr. Fariborz Kamal Ph.D.Chief Technical Advisor · born 1963
- Ms. Theresa JankeCo-Founder & Chief of Staff · born 1975
- Julian PeiHead of Investor Relations & Corporate Finance
- Dr. Katy Barglow Ph.D.Chief Technical Officer
- Dr. Scott P. Bizily J.D., Ph.D.Chief Legal Officer & Corporate Secretary · born 1972
- Dr. An Song Ph.D.Chief Translational Medicine Advisor
- Dr. Noriyuki Kasahara M.D., Ph.D.Chief Scientific Advisor · born 1963